Sustained-Release Eye Implant Outperforms Standard Injections for Wet AMD
A VEGF inhibitor implant preserved vision in 74% of wet AMD patients at 36 weeks, beating standard aflibercept therapy in a phase III trial.
Summary
A sustained-release eye implant called OTX-TKI showed superior results compared to standard anti-VEGF injections for wet age-related macular degeneration (AMD). In a phase III randomized trial, 74% of patients using the axitinib implant maintained good baseline visual acuity at 36 weeks, versus 56% on standard aflibercept. The implant also reduced the need for rescue injections, with three-quarters of implant patients requiring none at 36 weeks. The device is a bioresorbable hydrogel that slowly releases axitinib directly into the eye, potentially replacing the burden of frequent injections. Researchers called it the first treatment to demonstrate durability beyond 9 months in this condition.
Detailed Summary
Age-related macular degeneration is the leading cause of vision loss in older adults, and wet AMD — the more aggressive form — requires repeated eye injections to prevent blindness. The treatment burden is significant, and many patients lose vision between appointments. A new sustained-release implant may change that equation.
The phase III SOL-1 trial compared OTX-TKI, a bioresorbable hydrogel implant releasing the VEGF inhibitor axitinib, against standard-dose aflibercept (Eylea) in patients with previously untreated wet AMD and preserved visual acuity. After two loading doses of aflibercept, patients were randomized to either treatment arm and followed for over a year.
The results were striking. At 36 weeks, 74.1% of OTX-TKI patients maintained good baseline visual acuity versus 55.8% on aflibercept. That advantage held at 52 weeks (65.9% vs 44.2%). Crucially, 75% of implant patients needed no rescue anti-VEGF therapy at 36 weeks, compared to 56.4% on standard therapy. Anatomical stability, measured by central subfield thickness, was also preserved.
The study population entered with relatively high baseline vision — a mean of 70 letters — meaning there was limited room for improvement. Maintaining that level of acuity therefore carries real clinical weight. Researchers noted this is the first trial demonstrating durability exceeding nine months, a meaningful milestone in AMD management.
Caveats remain. About 25% of implant patients still lost durable visual acuity, and no biomarkers currently predict who will respond. The trial was presented at a conference and has not yet been published in a peer-reviewed journal. Still, for older adults managing wet AMD, a long-lasting implant reducing injection frequency while preserving vision represents a potentially significant quality-of-life advance.
Key Findings
- 74% of OTX-TKI implant patients maintained good visual acuity at 36 weeks vs 56% on standard injections
- Implant advantage persisted at 52 weeks: 65.9% vs 44.2% maintaining baseline visual acuity
- 75% of implant patients required no rescue anti-VEGF therapy at 36 weeks
- First AMD treatment to demonstrate durability exceeding 9 months in a randomized trial
- Bioresorbable hydrogel implant fully dissolves, eliminating need for surgical removal
Methodology
This is a meeting coverage news report from MedPage Today summarizing phase III randomized trial (SOL-1) results presented at the ARVO 2026 conference. The evidence basis is a controlled trial with 52-week follow-up, though full peer-reviewed publication is pending. MedPage Today is a credible medical news outlet targeting clinicians.
Study Limitations
Results were presented at a conference and have not yet been peer-reviewed or published in full. No predictive biomarkers exist for the ~25% of patients who fail to maintain durable vision. Long-term safety data beyond 52 weeks and real-world effectiveness data are not yet available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.